Progyny (PGNY) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

$0.55

Estimate

$0.53

Surprise

+4.6%

Score at report (before → after)

5.9 → 6.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Progyny (PGNY) beat the $0.53 estimate with adjusted EPS of $0.55 — a clear 4.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Hold at 6.2/10 after the report.

TrendMatrix currently rates PGNY Hold at 6.0/10.

4 of the last 4 quarters beat the estimate; this quarter's +4.6% surprise compares with a +13.7% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$25.97

Price target

$29.94

Stop

$24.49

Upside to target

+15.3%

Reward-to-risk

2.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Healthcare Plans

Market cap

$1.98B

P/E (fwd)

11.1

P/E (ttm)

28.4

52-week range

$16.10–$33.06

Off 52-week high

21.5%

RSI (14)

44

Volume vs avg

1.18×

Score today

6.0/10